The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of analgesics and antidepressants on TREK-2 and TRESK currents

  • Park, Hyun (Department of Neurosurgery, Gyeongsang National University Hospital, College of Medicine and Institute of Health Sciences, Gyeongsang National University) ;
  • Kim, Eun-Jin (Department of Physiology, College of Medicine and Institute of Health Sciences, Gyeongsang National University) ;
  • Han, Jaehee (Department of Physiology, College of Medicine and Institute of Health Sciences, Gyeongsang National University) ;
  • Han, Jongwoo (Department of Neurosurgery, Gyeongsang National University Hospital, College of Medicine and Institute of Health Sciences, Gyeongsang National University) ;
  • Kang, Dawon (Department of Physiology, College of Medicine and Institute of Health Sciences, Gyeongsang National University)
  • Received : 2016.02.04
  • Accepted : 2016.05.09
  • Published : 2016.07.01
Download PDF
⟨ Previous Next ⟩

Abstract

TWIK-related $K^+$ channel-2 (TREK-2) and TWIK-related spinal cord $K^+$ (TRESK) channel are members of two-pore domain $K^+$ channel family. They are well expressed and help to set the resting membrane potential in sensory neurons. Modulation of TREK-2 and TRESK channels are involved in the pathogenesis of pain, and specific activators of TREK-2 and TRESK may be beneficial for the treatment of pain symptoms. However, the effect of commonly used analgesics on TREK-2 and TRESK channels are not known. Here, we investigated the effect of analgesics on TREK-2 and TRESK channels. The effects of analgesics were examined in HEK cells transfected with TREK-2 or TRESK. Amitriptyline, citalopram, escitalopram, and fluoxetine significantly inhibited TREK-2 and TRESK currents in HEK cells (p<0.05, n=10). Acetaminophen, ibuprofen, nabumetone, and bupropion inhibited TRESK, but had no effect on TREK-2. These results show that all analgesics tested in this study inhibit TRESK activity. Further study is needed to identify the mechanisms by which the analgesics modulate TREK-2 and TRESK differently.

Keywords

References

  1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet . 2015;386:743-800. https://doi.org/10.1016/S0140-6736(15)60692-4
  2. Hall-Flavin DK, Winner JG, Allen JD, Jordan JJ, Nesheim RS, Snyder KA, Drews MS, Eisterhold LL, Biernacka JM, Mrazek DA. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012;2:e172. https://doi.org/10.1038/tp.2012.99
  3. Yan J, Dussor G. Ion channels and migraine. Headache. 2014;54:619-639. https://doi.org/10.1111/head.12323
  4. Cohen GL. Migraine prophylactic drugs work via ion channels. Med Hypotheses. 2005;65:114-122. https://doi.org/10.1016/j.mehy.2005.01.027
  5. Tsantoulas C, McMahon SB. Opening paths to novel analgesics: the role of potassium channels in chronic pain. Trends Neurosci. 2014;37:146-158. https://doi.org/10.1016/j.tins.2013.12.002
  6. Kang D, Kim D. TREK-2 (K2P10.1) and TRESK (K2P18.1) are major background $K^+$ channels in dorsal root ganglion neurons. Am J Physiol Cell Physiol. 2006;291:C138-146. https://doi.org/10.1152/ajpcell.00629.2005
  7. Lafreniere RG, Cader MZ, Poulin JF, Andres-Enguix I, Simoneau M, Gupta N, Boisvert K, Lafreniere F, McLaughlan S, Dube MP, Marcinkiewicz MM, Ramagopalan S, Ansorge O, Brais B, Sequeiros J, Pereira-Monteiro JM, Griffiths LR, Tucker SJ, Ebers G, Rouleau GA. A dominant-negative mutation in the TRESK potassium channel is linked to familial migraine with aura. Nat Med. 2010;16: 1157-1160. https://doi.org/10.1038/nm.2216
  8. Pereira V, Busserolles J, Christin M, Devilliers M, Poupon L, Legha W, Alloui A, Aissouni Y, Bourinet E, Lesage F, Eschalier A, Lazdunski M, Noel J. Role of the TREK2 potassium channel in cold and warm thermosensation and in pain perception. Pain. 2014;155:2534-2544. https://doi.org/10.1016/j.pain.2014.09.013
  9. Acosta C, Djouhri L, Watkins R, Berry C, Bromage K, Lawson SN. TREK2 expressed selectively in IB4-binding C-fiber nociceptors hyperpolarizes their membrane potentials and limits spontaneous pain. J Neurosci. 2014;34:1494-1509. https://doi.org/10.1523/JNEUROSCI.4528-13.2014
  10. Kollert S, Dombert B, Doring F, Wischmeyer E. Activation of TRESK channels by the inflammatory mediator lysophosphatidic acid balances nociceptive signalling. Sci Rep. 2015;5:12548. https://doi.org/10.1038/srep12548
  11. Liu P, Xiao Z, Ren F, Guo Z, Chen Z, Zhao H, Cao YQ. Functional analysis of a migraine-associated TRESK $K^+$ channel mutation. J Neurosci. 2013;33:12810-12824. https://doi.org/10.1523/JNEUROSCI.1237-13.2013
  12. Mathie A, Veale EL. Two-pore domain potassium channels: potential therapeutic targets for the treatment of pain. Pflugers Arch. 2015;467:931-943. https://doi.org/10.1007/s00424-014-1655-3
  13. Wolkerstorfer A, Handler N, Buschmann H. New approaches to treating pain. Bioorg Med Chem Lett. 2016;26:1103-1119. https://doi.org/10.1016/j.bmcl.2015.12.103
  14. Mika J, Zychowska M, Makuch W, Rojewska E, Przewlocka B. Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacol Rep 2013;65:1611-1621. https://doi.org/10.1016/S1734-1140(13)71522-6
  15. Khouzam HR. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. Postgrad Med. 2016;128:323-330. https://doi.org/10.1080/00325481.2016.1147925
  16. Jesse CR, Wilhelm EA, Nogueira CW. Depression-like behavior and mechanical allodynia are reduced by bis selenide treatment in mice with chronic constriction injury: a comparison with fluoxetine, amitriptyline, and bupropion. Psychopharmacology (Berl). 2010;212:513-522. https://doi.org/10.1007/s00213-010-1977-6
  17. Moore R, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 7:CD008242.
  18. Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc. 2015;90:532-545. https://doi.org/10.1016/j.mayocp.2015.01.018
  19. Saarto T, Wiffen PJ. Antidepressants for treating neuropathic pain. Cochrane Database Syst Rev 2007:CD005454.
  20. Nielsen JC, Bjerring P, Arendt-Nielsen L, Petterson KJ. Analgesic efficacy of immediate and sustained release paracetamol and plasma concentration of paracetamol. Double blind, placebo-controlled evaluation using painful laser stimulation. Eur J Clin Pharmacol. 1992;42:261-264.
  21. Mehlisch DR, Sykes J. Ibuprofen blood plasma levels and onset of analgesia. Int J Clin Pract Suppl. 2013;(178):3-8.
  22. Baeck SK, Lim MA, Park SY, Lee JS, Lee HS, Koo KS. Blood concentrations of amitriptyline and its metabolite in rats after acute oral administration of amitriptyline. J Anal Toxicol. 2000;24:271-274. https://doi.org/10.1093/jat/24.4.271
  23. Laib AK, Brunen S, Pfeifer P, Vincent P, Hiemke C. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Ther Drug Monit. 2014;36:473-479. https://doi.org/10.1097/FTD.0000000000000042
  24. Paulzen M, Grunder G, Veselinovic T, Wolf B, Hiemke C, Lammertz SE. Duloxetine enters the brain - But why is it not found in the cerebrospinal fluid. J Affect Disord. 2016;189:159-163. https://doi.org/10.1016/j.jad.2015.08.073
  25. Reis M, Cherma MD, Carlsson B, Bengtsson F. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit. 2007;29:758-766. https://doi.org/10.1097/FTD.0b013e31815b3f62
  26. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry. 1997;154:963-969. https://doi.org/10.1176/ajp.154.7.963
  27. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 1993;5:322-329. https://doi.org/10.1176/jnp.5.3.322
  28. Brueggemann LI, Mani BK, Mackie AR, Cribbs LL, Byron KL. Novel actions of nonsteroidal anti-inflammatory drugs on vascular ion channels: accounting for cardiovascular side effects and identifying new therapeutic applications. Mol Cell Pharmacol. 2010;2:15-19.
  29. Martin DK, Schyvens CG, Wyse KR, Bursill JA, Owe-Young RA, Macdonald PS, Campbell TJ. Role of non-steroidal antiinflammatory drugs (NSAIDs) in modulating vascular smooth muscle cells by activating large-conductance potassium ion channels. Patch Clamp Technique. 2012;14:283-300.
  30. Freeman LC, Narvaez DF, McCoy A, von Stein FB, Young S, Silver K, Ganta S, Koch D, Hunter R, Gilmour RF, Lillich JD. Depolarization and decreased surface expression of $K^+$ channels contribute to NSAID-inhibition of intestinal restitution. Biochem Pharmacol. 2007;74:74-85. https://doi.org/10.1016/j.bcp.2007.03.030
  31. Heldestad A, Jonsborg S, Henriksson R, Grankvist K. Acetaminophen protection against estramustine-induced cytotoxicity on cultured fibroblasts. Pharmacol Toxicol. 1998;82:128-131. https://doi.org/10.1111/j.1600-0773.1998.tb01411.x
  32. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thummler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM, Debonnel G, Lazdunski M. Deletion of the background potassium channel TREK-1 results in a depressionresistant phenotype. Nat Neurosci. 2006;9:1134-1141. https://doi.org/10.1038/nn1749
  33. Gotter AL, Santarelli VP, Doran SM, Tannenbaum PL, Kraus RL, Rosahl TW, Meziane H, Montial M, Reiss DR, Wessner K, McCampbell A, Stevens J, Brunner JI, Fox SV, Uebele VN, Bayliss DA, Winrow CJ, Renger JJ. TASK-3 as a potential antidepressant target. Brain Res. 2011;1416:69-79. https://doi.org/10.1016/j.brainres.2011.08.021
  34. Borsotto M, Veyssiere J, Moha Ou Maati H, Devader C, Mazella J, Heurteaux C. Targeting two-pore domain $K^+$ channels TREK-1 and TASK-3 for the treatment of depression: a new therapeutic concept. Br J Pharmacol. 2015;172:771-784. https://doi.org/10.1111/bph.12953
  35. Kang D, Kim GT, Kim EJ, La JH, Lee JS, Lee ES, Park JY, Hong SG, Han J. Lamotrigine inhibits TRESK regulated by G-protein coupled receptor agonists. Biochem Biophys Res Commun. 2008;367:609-615. https://doi.org/10.1016/j.bbrc.2008.01.008
  36. Kim CW, Choe C, Kim EJ, Lee JI, Yoon SY, Cho YW, Han S, Tak HM, Han J, Kang D. Dual effects of fluoxetine on mouse early embryonic development. Toxicol Appl Pharmacol. 2012;265:61-72. https://doi.org/10.1016/j.taap.2012.09.020
  37. Semenchuk MR, Davis B. Efficacy of sustained-release bupropion in neuropathic pain: an open-label study. Clin J Pain. 2000;16:6-11. https://doi.org/10.1097/00002508-200003000-00002
  38. Vazquez-Gomez E, Arias HR, Feuerbach D, Miranda-Morales M, Mihailescu S, Targowska-Duda KM, Jozwiak K, Garcia-Colunga J. Bupropion-induced inhibition of ${\alpha}$7 nicotinic acetylcholine receptors expressed in heterologous cells and neurons from dorsal raphe nucleus and hippocampus. Eur J Pharmacol. 2014;740:103-111. https://doi.org/10.1016/j.ejphar.2014.06.059
  39. Yang Y, Shimomura K, Sakuma K, Maejima Y, Iwasaki Y, Galvanovskis J, Dezaki K, Nakata M, Yada T. Bupropion can close KATP channel and induce insulin secretion. J Pediatr Endocrinol Metab. 2013;26:343-346.
  40. Kang D, Han J, Kim D. Mechanism of inhibition of TREK-2 (K2P10.1) by the Gq-coupled M3 muscarinic receptor. Am J Physiol Cell Physiol. 2006;291:C649-656. https://doi.org/10.1152/ajpcell.00047.2006
  41. Czirjak G, Toth ZE, Enyedi P. The two-pore domain $K^+$ channel, TRESK, is activated by the cytoplasmic calcium signal through calcineurin. J Biol Chem. 2004;279:18550-18558. https://doi.org/10.1074/jbc.M312229200
  42. Veale EL, Mathie A. Aristolochic acid, a plant extract used in the treatment of pain and linked to Balkan endemic nephropathy, is a regulator of K2P channels. Br J Pharmacol. 2016;173:1639-1652. https://doi.org/10.1111/bph.13465
  43. Bang H, Kim Y, Kim D. TREK-2, a new member of the mechanosensitive tandem-pore $K^+$ channel family. J Biol Chem. 2000; 275:17412-17419. https://doi.org/10.1074/jbc.M000445200
  44. Kang D, Mariash E, Kim D. Functional expression of TRESK-2, a new member of the tandem-pore $K^+$ channel family. J Biol Chem. 2004;279:28063-28070. https://doi.org/10.1074/jbc.M402940200
  45. Rahm AK, Gierten J, Kisselbach J, Staudacher I, Staudacher K, Schweizer PA, Becker R, Katus HA, Thomas D. PKC-dependent activation of human $K_2p$ 18.1 $K^+$ channels. Br J Pharmacol. 2012;166:764-773. https://doi.org/10.1111/j.1476-5381.2011.01813.x
  46. Enyedi P, Czirjak G. Properties, regulation, pharmacology, and functions of the $K_2p$ channel, TRESK. Pflugers Arch. 2015;467:945-958. https://doi.org/10.1007/s00424-014-1634-8
  47. Callejo G, Giblin JP, Gasull X. Modulation of TRESK background $K^+$ channel by membrane stretch. PLoS One. 2013;8:e64471. https://doi.org/10.1371/journal.pone.0064471
  48. Guo D, Hu J. Spinal presynaptic inhibition in pain control. Neuroscience. 2014;283:95-106. https://doi.org/10.1016/j.neuroscience.2014.09.032

Cited by

  1. Selective and state-dependent activation of TRESK (K2P18.1) background potassium channel by cloxyquin : State-dependent activation of TRESK (K2P18.1) by cloxyquin vol.174, pp.13, 2016, https://doi.org/10.1111/bph.13821
  2. Identification of critical amino acids in the proximal C-terminal of TREK-2 K+ channel for activation by acidic pHi and ATP-dependent inhibition vol.470, pp.2, 2016, https://doi.org/10.1007/s00424-017-2072-1
  3. Tandem pore TWIK-related potassium channels and neuroprotection vol.14, pp.8, 2016, https://doi.org/10.4103/1673-5374.253506
  4. TRESK (K2P18.1) Background Potassium Channel Is Activated by Novel-Type Protein Kinase C via Dephosphorylation vol.95, pp.6, 2016, https://doi.org/10.1124/mol.119.116269
  5. TREK-2 Mediates the Neuroprotective Effect of Isoflurane Preconditioning Against Acute Cerebral Ischemia in the Rat vol.22, pp.4, 2016, https://doi.org/10.1089/rej.2017.2039
  6. Block of TREK and TRESK K2P channels by lamotrigine and two derivatives sipatrigine and CEN-092 vol.26, pp.None, 2016, https://doi.org/10.1016/j.bbrep.2021.101021
  7. Negative Influence by the Force: Mechanically Induced Hyperpolarization via K2P Background Potassium Channels vol.22, pp.16, 2021, https://doi.org/10.3390/ijms22169062